synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
This balance-of-power principle, once formulated, became an axiom of political science. Fénelon, in his Instructions, impressed the axiom upon the young French Dauphin. Frederick the Great, in his Anti-Machiavel, proclaimed the principle to the world. In 1806, Friedrich von Gentz re-stated it with admirable clarity, in Fragments on the Balance of Power. The principle formed the basis of the coalitions against Louis XIV and Napoleon, and the occasion (or excuse) for most of the European wars between the Peace of Westphalia (1648) and the Congress of Vienna (1814). It was especially championed by Great Britain, even up to World War I, as it sought to prevent a European land power from rivaling its naval supremacy. During the greater part of the 19th century, the series of national upheavals which remodeled the map of Europe obscured the balance of power. Yet, it underlaid all the efforts of diplomacy to tame the forces of nationalism let loose by the French Revolution. In the revolution's aftermath, with the restoration of comparative calm, the principle once more emerged as the operative motive for the various political alliances, of which the ostensible object was the preservation of peace. Regarding the era 1848–1914, English diplomatic historian A.J.P. Taylor argued:
== History == Cell display systems were first used in 1985, when peptides were genetically fused with proteins displayed on the M13 bacteriophage. Bacteriophage display is a commonly used cell display system, although it carries limitations in the size of proteins that can be displayed. Bacterial display was then introduced in 1986, allowing the surface display of larger proteins. Bacterial display systems were first introduced by Freudl et al. and Charbit et al. in 1986, when they used bacterial surface proteins OmpA and LamB to display peptides. Freudl et al. fused peptides with linkers with the ompA gene, causing the peptides to be expressed in the OmpA proteins. They showed that the proteins were now subject to cleavage by proteinase K. The non-OmpA peptides inserted were therefore a target of proteinase K. Insertion of the foreign peptides did not affect bacterial cell growth. Charbit et al. firstly defined the areas of the LamB protein that were "permissive" for foreign petide insertion (ie that did not lead to a complete loss of functionality of the protein). Then, they explored the versatility of the permissive sites (size limit, nature of the epitope,...) that were all located in surface-exposed loops of the trimeric outer membrane porin, aiming at developing multivalent live bacterial vaccines. This was the first evidence of using bacterial surface display techniques to express proteins on the surface of cells, without altering the function of the cell.
==== Cell surface receptors ==== The extracellular environment is able to induce changes within the cell. Hormones, or other extracellular signals, are able to induce changes within the cell by binding to cell surface receptors also known as transmembrane receptors. This interaction allows the hormone receptor to produce second messengers within the cell to aid response. Second messengers may also be sent to interact with intracellular receptors in order to enter the complex signal transport system that eventually changes cellular function. G-protein-coupled membrane receptors (GPCR) are a major class of transmembrane receptors. The features of G proteins include GDP/GTP binding, GTP hydrolysis and guanosine nucleotide exchange. When a ligand binds to a GPCR the receptor changes conformation, which makes the intracellular loops between the different membrane domains of the receptor interact with G proteins. This interaction causes the exchange of GDP for GTP, which triggers structural changes within the alpha subunit of the G protein. The changes interrupts the interaction of the alpha subunit with the beta–gamma complex and which results in a single alpha subunit with GTP bound and a beta–gamma dimer. The GTP–alpha monomer interacts with a variety of cellular targets. The beta–gamma dimer also can stimulate enzymes within the cells for example, adenylate cyclase but it does not have as many targets as the GTP–alpha complex.
Sources: en.wikipedia.org
The chancellor of Germany is the political leader of Germany and the head of the federal government. The office holder is responsible for selecting all other members of the government and chairing cabinet meetings. The office was created in the North German Confederation in 1867, when Otto von Bismarck became the first chancellor. With the unification of Germany and establishment of the German Empire in 1871, the Confederation evolved into a German nation-state and its leader became known as the chancellor of Germany. Originally, the chancellor was only responsible to the emperor. This changed with the constitutional reform in 1918, when the Parliament was given the right to dismiss the chancellor. Under the 1919 Weimar Constitution the chancellors were appointed by the directly elected president, but were responsible to the Reichstag (parliament). The constitution was set aside during the 1933–1945 Nazi regime. During the Allied occupation, no independent German government and no chancellor existed; and the office was not reconstituted in East Germany, thus the head of government of East Germany was chairman of the Council of Ministers. The 1949 Basic Law made the chancellor the most important office in West Germany, while diminishing the role of the president.
==== MeSH D06.472.931 – thyroid hormones ==== MeSH D06.472.931.103 – dextrothyroxine MeSH D06.472.931.208 – diiodotyrosine MeSH D06.472.931.388 – monoiodotyrosine MeSH D06.472.931.669 – thyroid gland, desiccated MeSH D06.472.931.740 – thyronines MeSH D06.472.931.740.180 – diiodothyronines MeSH D06.472.931.740.385 – triiodothyronine MeSH D06.472.931.740.590 – triiodothyronine, reverse MeSH D06.472.931.812 – thyroxine
=== European Union === In 2000, the European Union (EU) enacted similar legislation, Regulation(EC) No 141/2000, which refers to drugs developed to treat rare diseases to as "orphan medicinal products". The EU's definition of an orphan condition is broader than that of the US, in that it also covers some tropical diseases that are primarily found in developing nations. Orphan drug status granted by the European Commission gives marketing exclusivity in the EU for 10 years after approval. The EU's legislation is administered by the Committee on Orphan Medicinal Products of the European Medicines Agency (EMA). In late 2007 the FDA and EMA agreed to use a common application process for both agencies to make it easier for manufacturers to apply for orphan drug status but, while continuing two separate approval processes.
In 2015, the Wildcats played in their fourth consecutive bowl game, defeating the University of New Mexico in the New Mexico Bowl. In 2017, they lost to the Purdue Boilermakers in the Foster Farms Bowl, the Wildcats 21st bowl game. Dave Heeke was named Arizona's 13th Director of Athletics in February 2017 and officially started in that role on April 1, 2017. Heeke served as Athletics Director at Central Michigan University for 11 years and as a staff member in the University of Oregon athletics department for 18 years. (Greg Byrne resigned from the post in January to accept the same role at the University of Alabama.) Rodriguez was relieved of his duties on January 2, 2018, in the wake of an internal university investigation of sexual harassment claims made by Rodriguez's former administrative assistant. After a nationwide search and much media speculation, Kevin Sumlin was hired on January 14, 2018, as the new Wildcats head football coach. Sumlin was head coach at Texas A&M University and the University of Houston. After a disappointing three-season tenure, with the Wildcats posting a 5–7 (4–5 in Pac-12) record in 2018 and a 4–8 record (2–7 in Pac-12) record in 2019, Sumlin was fired at the conclusion of the 2020 season (a truncated schedule due to the COVID-19 pandemic). After a nationwide search and much media speculation, former college and NFL coach Jedd Fisch (most recently the QB coach for the New England Patriots and a previous assistant at UCLA, Michigan, Miami and Minnesota) was chosen as the Wildcats' 32nd head football coach, as announced in December 2020.
Sources: en.wikipedia.org
Research shows that children who participate in Head Start are more likely to eat better than children who don't participate in this program. Solutions to worldwide obesity problems require unique approaches that include lifestyle changes, health policies, advancements of healthcare, involvement of parents and concerned citizens and education to prevent this problem from escalating. Several school districts have banned sodas, junk foods and candy from vending machines and cafeterias. Programs have been formed to help improve this health crisis such as, Lets Move, Eat Smart, Move More, Weigh Less, and Weight Watchers are just a few that have helped people lose weight. Some towns have initiatives that are safe routes for children to walk or ride their bikes. This program is called "Safe Routes to School". Educational programs such as Head Start have been created to offer federal funded school meals to children. This was one way of teaching children about healthy choices and good nutrition. Also, to help reduce obesity, the federal and local governments in the United States have asked food and beverage industries to label all foods and drinks. These labels help consumers be more conscious about the foods and drinks they are buying. Make America Healthy Again is a campaign led by Robert F. Kennedy Jr. during The Second Trump administration. MAHA became a commitment to Donald Trump's 2024 Presidential campaign after Robert F. Kennedy Jr. suspended his campaign. Trump established The MAHA commission on February 13, 2025 to study and recommend policies on the U.S.
As a result, while the use of 1–3 mm microbore columns and lower flow rates of 50–200 μl/min was commonly considered necessary for optimum operation in the past, this limitation is no longer as important, and the higher column capacity of larger bore columns can now be advantageously employed with ESI LC–MS systems. Positively and negatively charged ions can be created by switching polarities, and it is possible to acquire alternate positive and negative mode spectra rapidly within the same LC run. While most large molecules (greater than MW 1500–2000) produce multiply charged ions in the ESI source, the majority of smaller molecules produce singly charged ions.
== Disaccharide phosphorylases == Different biocatalytic approaches have been developed toward the synthesis of glycosides in past decades, for which glycosyltransferases and glycoside hydrolases are among the most common catalysts. The former often needs expensive materials and the latter often shows low yields. De Winter et al. investigated use of cellobiose phosphorylase (CP) toward synthesis of alpha-glycosides in ionic liquids. The best condition for use of CP was found to be in the presence of the ionic liquid AMMOENG 101 and ethyl acetate.
== Cited sources == Martin, Archer J. P. (December 12, 1952). "The development of partition chromatography. Nobel Lecture" (PDF). Nobel Lectures, Chemistry 1942–1962. Amsterdam: Elsevier. Ettre, Leslie Stephen (2001). "The Predawn of Paper Chromatography". Chromatographia. 54 (5–6): 409–414. doi:10.1007/BF02492694. S2CID 95357195. Touchstone, Joseph C. (1993). "History of Chromatography". Journal of Liquid Chromatography. 16 (8): 1647–1665. doi:10.1080/10826079308021679.
=== Destruction and preservation === Because of its waterlogged condition the Flag Fen Basin was an area where peat deposits developed around 2000 BC, and they survive there today. The anaerobic conditions generated by silt deposits from the fens protected the wooden posts and rafters of the collapsed structures from rotting away under the influence of air and bacteria. In the 10th century BC the ground level was much lower than today, increasing around 1 mm (0.039 inches) per year as autumnal debris was added to the surface of the fens. By the early Roman period most of the structure was covered and preserved.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.